- Home
- CUB vs DCTH Comparison
CUB vs DCTH Comparison
Compare CUB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- DCTH
- Stock Information
- Founded
- CUB 2024
- DCTH 1988
- Country
- CUB United States
- DCTH United States
- Employees
- CUB N/A
- DCTH N/A
- Industry
- CUB
- DCTH Medical/Dental Instruments
- Sector
- CUB
- DCTH Health Care
- Exchange
- CUB NYSE
- DCTH Nasdaq
- Market Cap
- CUB 322.0M
- DCTH 485.5M
- IPO Year
- CUB 2024
- DCTH N/A
- Fundamental
- Price
- CUB $10.46
- DCTH $12.50
- Analyst Decision
- CUB
- DCTH Strong Buy
- Analyst Count
- CUB 0
- DCTH 4
- Target Price
- CUB N/A
- DCTH $24.00
- AVG Volume (30 Days)
- CUB 50.4K
- DCTH 785.8K
- Earning Date
- CUB 08-22-2025
- DCTH 08-04-2025
- Dividend Yield
- CUB N/A
- DCTH N/A
- EPS Growth
- CUB N/A
- DCTH N/A
- EPS
- CUB 0.34
- DCTH N/A
- Revenue
- CUB N/A
- DCTH $53,850,000.00
- Revenue This Year
- CUB N/A
- DCTH $155.42
- Revenue Next Year
- CUB N/A
- DCTH $37.93
- P/E Ratio
- CUB $31.16
- DCTH N/A
- Revenue Growth
- CUB N/A
- DCTH 1068.87
- 52 Week Low
- CUB $9.96
- DCTH $7.17
- 52 Week High
- CUB $10.61
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- DCTH 33.81
- Support Level
- CUB N/A
- DCTH $13.30
- Resistance Level
- CUB N/A
- DCTH $14.15
- Average True Range (ATR)
- CUB 0.00
- DCTH 0.64
- MACD
- CUB 0.00
- DCTH -0.26
- Stochastic Oscillator
- CUB 0.00
- DCTH 8.28
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.